Published 5 days ago • loading... • Updated 5 days ago

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Summary by Weatherford Democrat

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025

2 Articles

All

Left

Center

Right

Reposted by

Weatherford Democrat

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025

5 days ago

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Total News Sources2

Leaning Left2Leaning Right0Center0Last Updated5 days agoBias Distribution

100% Left

100% Left

To view factuality data please Upgrade to Premium

To view ownership data please Upgrade to Vantage

Weatherford Democrat broke the news in 5 days ago on Tuesday, June 24, 2025.

Sources are mostly out of (0)